Antigen targeting peptide nano-micelle and its use

The activation of antiviral immune memory in the tumor microenvironment through antigen-targeting peptide nanomiles is solved, and the complexity of target selection and changes in expression patterns in cancer immunotherapy is achieved, effective targeting and killing of tumors is achieved, and the stability and targeting of the treatment effect are improved.

CN119158012BActive Publication Date: 2025-03-18ZHEJIANG CANCER HOSPITAL
2 Cites 0 Cited by

Patent Information

Application Number
CN202411692022.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-11-25
Publication Date
2025-03-18
Estimated Expiration
2044-11-25

AI Technical Summary

Technical Problem

Existing cancer immunotherapy faces the problem of complexity of target selection and dynamic changes in target expression patterns, which leads to unstable treatment effects, especially in heterogeneous and rare tumors.

Method used

An antigen-targeting peptide nanomilk is adopted, which is formed by self-assembly of the fusion peptide of PEG polymer and specific sequences, which can release and activate antiviral immune memory in the tumor microenvironment, simulate a "meglobal virus" to activate pre-existing antiviral immune responses, and then target and kill tumor cells.

Benefits of technology

Significantly improve the intratumor immune microenvironment, enhance the tumor targeting ability, avoid damage to normal cells, achieve effective killing of tumors, and convert antiviral immunity into anti-tumor immunity, and improve the survival rate and proportion of immune cells in pre-immunized mice.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses an antigen targeting peptide nano-micelle and its use, belongs to the field of biomedicine, and specifically relates to an antigen targeting peptide molecule, which is composed of polyethylene glycol as a hydrophilic component, and a hydrophobic region comprising a matrix metalloproteinase-2 restriction site, a preS1 antigen peptide and a low pH insertion peptide. The antigen targeting peptide nano-micelle is made of antigen targeting peptide molecules by self-assembly technology. The antigen targeting peptide nano-micelle of the present invention has precise tumor microenvironment responsiveness, can release antigen peptides in TME, and anchor the preS1 epitope to the tumor cell membrane through pHLIP to simulate the viral mechanism. The present invention can reshape the tumor immune microenvironment, induce tumor cells to display viral antigen peptides, and then activate the pre-existing antiviral immune response, and achieve antibody-mediated tumor cell killing.
Need to check novelty before this filing date? Find Prior Art